Merck and Moderna Report 42 Percent Drop in Melanoma Risk With mRNA Vaccine
Late-stage trial data shows personalized mRNA vaccines significantly reduce death and recurrence rates for patients with advanced skin cancer.
By Adrian Salazar ·

Personalized mRNA vaccines for melanoma reduced the risk of death or cancer recurrence by 42 percent compared to standard care, according to late-stage trial results announced by Merck and Moderna on Thursday. The findings represent a major breakthrough in treating the deadliest form of skin cancer and mark a pivotal moment for the use of mRNA technology in oncology. The pharmaceutical partners stated they are already working with regulatory authorities to secure approval for the new treatment.
The trial results were presented at the European Society of Medical Oncology conference in Madrid, Spain. While the full data was scheduled for release on Saturday, the companies accelerated the announcement after an oncology news site reported the findings early, breaking the agreed-upon embargo. The complete dataset has been accepted for publication in the New England Journal of Medicine, further validating the scientific rigor of the study.
To understand the scale of this development, it is helpful to look back at the trial's timeline. The Phase 3 study enrolled 1,137 patients who had stage IIB through IV melanoma that had been surgically removed before they joined the trial. Participants were randomized in a two-to-one ratio. This meant two-thirds of the patients received the personalized mRNA vaccine in combination with standard treatment, while the remaining third received only the standard therapy.
The standard treatment used in the trial was Keytruda, a well-known monoclonal antibody cancer drug manufactured by Merck. By comparing the outcomes of the two groups, researchers were able to isolate the specific benefit provided by the addition of the mRNA vaccine. The 42 percent reduction in the risk of death or recurrence is a substantial improvement over the existing standard of care for these advanced stages of melanoma.
Moderna CEO Stéphane Bancel highlighted the strategic importance of the results in a company statement. He noted that the company has long believed mRNA technology could enable the development of cancer treatments uniquely matched to each patient's specific tumor. Bancel described the trial results as a defining moment for that vision, suggesting they demonstrate what is possible when the approach to medicine is rethought.
The executive emphasized that the success of this trial reinforces the conviction that mRNA has the potential to fundamentally change how cancer is treated. This is not just a single product win but a broader validation of the platform technology. The ability to create individualized medicines targets the unique genetic mutations present in a patient's cancer, offering a more precise approach than traditional therapies.
The announcement comes less than three months after the companies first confirmed that the vaccine had succeeded in the trial. In August, Merck and Moderna reported the success but held back the specific details until the data could be formally presented at a major scientific conference. The delay was a strategic choice to ensure the findings were reviewed by the peer oncology community in a structured setting.
Now that the top-line results are public, the focus shifts to the regulatory process. Both companies are engaging with health authorities to move toward approval. This next phase will determine how quickly the vaccine can become available to patients worldwide. The speed of this engagement suggests a high level of confidence in the data and a desire to bring the therapy to market as soon as possible.
For patients in New York and New Jersey, and across the country, this news offers a new avenue of hope. Melanoma is often aggressive, and late-stage cases have historically been difficult to manage. A 42 percent reduction in serious outcomes is a significant statistic that could change treatment protocols for thousands of individuals. The integration of personalized mRNA vaccines into standard care marks a new paradigm in cancer therapy.
The full data will soon be available in the New England Journal of Medicine, allowing other researchers and doctors to review the detailed methodology and outcomes. Until then, the headline figure of a 42 percent risk reduction stands as the most consequential fact for patients and providers alike. The partnership between Merck and Moderna has delivered a clear, measurable benefit that positions mRNA technology as a cornerstone of future cancer treatment.






